Valneva’s ADR jumps on the Nasdaq after the start of recalls on its Covid vaccine

NEW YORK (Agefi-Dow Jones)–Valneva’s American depository share (ADR) climbed 12.5% ​​to $35.6 on the Nasdaq on Tuesday, after the biotech company announced it had started booster vaccinations of its phase 3 clinical study conducted on its anti-Covid vaccine.

“This recall phase is intended to provide additional data on homologous recalls as well as first data on heterologous recalls, to complement the previous positive recall data generated in phase 1/2,” the report said. laboratory in a press release. A homologous booster uses the same vaccine as during the initial vaccination unlike a heterologous booster.

Valneva clarified that this data was not required for initial marketing authorization applications that the company expects to finalize in the coming weeks.

The clinical trial extension will evaluate a booster dose of Valneva’s “VLA2001” vaccine in adults aged 18 years and over, who received a primary series with two doses of the same vaccine, as well as in participants, aged 30 years and older, who received two doses of AstraZeneca’s “AZD1222” vaccine.

Valneva’s booster vaccine will be administered at least seven months after the end of the primary series. Early data is expected in the second quarter of 2022, the company said.

Valneva shares closed down 0.1% to 14.2 euros on Tuesday at the Paris Stock Exchange.

-Chris Wack, The Wall Street Journal (French version François Berthon) ed: ECH

Agefi-Dow Jones The financial newswire

Dow Jones Newswires

January 25, 2022 13:13 ET (18:13 GMT)

Source link -91